Nov 02, 2017 12:30 pm UTC| Business
No Treatment Related Adverse Events Reported; Key Data Points Trend Positive NEW YORK, Nov. 02, 2017 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric...
Edgewater Reports Third Quarter 2017 Results
Nov 02, 2017 12:30 pm UTC| Business
WAKEFIELD, Mass., Nov. 02, 2017 -- Edgewater Technology, Inc. (NASDAQ:EDGW), a leading consulting firm that helps business leaders drive transformational change through its unique selection of business and technology...
Advanced Defense Technologies, Inc. (ADCF) Announces Removal of “Stop Sign”
Nov 02, 2017 12:30 pm UTC| Business
NEW YORK, Nov. 02, 2017 -- Advanced Defense Technologies, Inc. (OTC PINK:ADCF) announces that it has submitted all necessary documentation to qualify as a limited information company on the OTC Markets. ADCF has...
Nov 02, 2017 12:30 pm UTC| Business
HAYWARD, Calif., Nov. 02, 2017 -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that data from the SOLUTION, Phase 3 clinical study of Sollpura (liprotamase) and an additional non-clinical study will be...
Impinj to Present at RBC Technology Conference
Nov 02, 2017 12:30 pm UTC| Business
SEATTLE, Nov. 02, 2017 -- Impinj, Inc. (NASDAQ:PI), a leading provider and pioneer of RAIN RFID solutions for identifying, locating and authenticating everyday items, today announced participation in the following...
Aqua Metals to Host Third Quarter 2017 Conference Call on Thursday, November 9th at 2:00 p.m. PT
Nov 02, 2017 12:30 pm UTC| Business
ALAMEDA, Calif., Nov. 02, 2017 -- Aqua Metals, Inc. (NASDAQ:AQMS), (“Aqua Metals” or the “Company”), which is proceeding to commercialize its proprietary electrochemical lead recycling technology called AquaRefining™,...
Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results
Nov 02, 2017 12:30 pm UTC| Business
NEWTOWN, Pa., Nov. 02, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on...